TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Prospective Study of Quality of Life in Adult Scoliosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged 40 to 80 years with~* ASLS defined as lumbar curve with a coronal Cobb measurement ≥ 30°, and either of the following: Oswestry Disability Index (ODI) score ≥ 20 or SRS-QOL score ≤ 4.0 in the domains of pain, function and/or appearance.~* If assigned to surgical intervention (by randomization or patient preference), the intervention plan would include, at a minimum, the Cobb levels of the Thoracolumbar/lumbar spine.~Exclusion Criteria:~* Substantial cardiac, pulmonary, renal or metabolic disease that, in the judgment of the surgical team, would preclude performing an operative procedure without undue risk of morbidity and mortality~* Concomitant high-grade spondylolisthesis (Grade 3)~* Prior thoracic or multiple level lumbar laminectomy or decompression \[single or two level lumbar decompression (e.g., herniated disc) will not be an exclusion\]~* Prior thoracic or lumbar fusion~* Osteoporosis evidence by a dual-energy x-ray absorptiometry (DEXA) T-score \<-3.0 at hip or lumbar spine for patients considered to be at risk (post menopausal females, males \> 60 years of age, steroid dependent rheumatoid arthritics, status post organ transplantation, etc.). Patients may be randomized prior to obtaining DEXA results. Non Surgical patients may initiate non surgical treatments prior to completion of DEXA (if required) as non surgical treatments will not affect DEXA results but DEXA must be completed and results entered within 3 months of enrollment. Surgical patient must have DEXA prior to surgical intervention.~* Neuromuscular scoliosis (e.g., spinal muscular atrophy, cerebral palsy, Parkinson's Disease, post-polio syndrome, Charcot Marie Tooth disease)~* Congenital scoliosis in the lumbar spine. Congenital anomalies of the cervical or thoracic spine are acceptable.~* Spine tumor, infection or connective tissue disorder~* Cognitively impaired or unable/unwilling to comply with follow-up~* Pregnancy or planning on conceiving during time of study involvement~* Ankylosing Spondylitis~* Past history of vertebroplasty or kyphoplasty of the thoracic or lumbar spine

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Surgical Intervention (Type: ACTIVE_COMPARATOR): None
- Non-Operative Intervention (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subjects must have a diagnosis of B cell CLL, measurable disease, and an~   NCI-WG indication for treatment with one of the following:~  * Massive (\>6 cm below left costal margin) or progressive splenomegaly;~  * Massive (\>10 cm longest diameter) lymph nodes, nodal clusters, or progressive lymphadenopathy;~  * Progressive anemia;~  * Progressive thrombocytopenia;~  * Weight loss \> 10% body weight over the preceding 6 month period;~  * Fatigue attributable to CLL;~  * Fever or night sweats without evidence of infection;~  * Progressive lymphocytosis.~2. Subjects must be age 18 years or older.~3. Women of childbearing potential (not postmenopausal for at least one year or not surgically incapable of bearing children) must agree not to become pregnant for the duration of the study. Both men and women participants must agree to use contraception for the duration of the study.~4. Subjects must have Zubrod performance status of ≤ 2 (Appendix B).~5. Subjects must have adequate hematologic, renal, hepatic, and coagulation function:~   * Adequate hematologic function:~     * Platelet count ≥ 50,000/μl; AND~    * Hemoglobin ≥ 10 g/dl (may be supported by erythropoietin or transfusion).~  * Adequate renal function:~     * Serum creatinine ≤ 1.5 times upper limit of normal; OR~    * Measured creatinine clearance ≥ 40 mL/min/1.73 m\^2.~  * Adequate hepatic function:~     * Total bilirubin ≤ 2.5 times upper limit of normal; AND~    * ALT ≤ 2.5 times upper limit of normal; AND~  * Adequate coagulation tests:~     * Prothrombin time international normalized ratio (INR) ≤ 2; AND~    * Partial thromboplastin time ≤ 1.66 times upper limit of normal~6. Subjects must be able to give written informed consent.~Exclusion Criteria:~1. Presence of more than 55% prolymphocytes.~2. Chemotherapy (e.g., purine analogues, alkylating agents, or corticosteroids), antibody therapy, immunotherapy, radiation therapy, or participation in any investigational drug treatment within 4 weeks of enrollment into protocol or at any time during the study.~3. Ongoing toxicity from prior anti-neoplastic therapy.~4. Prior gene therapy or allogeneic stem cell transplantation.~5. Untreated autoimmune hemolytic anemia or immune thrombocytopenia.~6. Active infection requiring parenteral antibiotics.~7. Known HIV/HBV/HCV seropositivity.~8. Uncompensated hypothyroidism (defined as TSH greater than 4x upper limit of normal not treated with replacement hormone).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness & Implementation of a Behavioral Intervention for Adherence and Substance Use in HIV Care in South Africa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV positive and on ART~* 18-65 years of age~* Elevated substance use risk (ASSIST score greater than or equal to 4 for drugs or greater than or equal to 11 for alcohol)~* Have at least one of the following:~  1. Not attained viral suppression from first line ART (VL\>400 copies/mL)~ 2. On second-line ART treatment~ 3. Reinitiated first-line treatment within the past three months~ 4. Had a pharmacy non-refill at least once in the past 3 months~Exclusion Criteria:~* Inability to provide informed consent or complete procedures in English or isiXhosa~* Severe risk/likely dependence for opiates (ASSIST score \>26) because opiate substitution therapy may not be available~* Severe alcohol dependence symptoms that may warrant medical management of potential withdrawal symptoms~* Active, untreated, major mental illness (with untreated psychosis or mania) that would interfere with the paraprofessional adapted intervention

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Project Khanya (Type: EXPERIMENTAL): Those assigned to Project Khanya (the behavioral intervention for substance use and adherence condition) will have approximately 6 sessions (including Life-Steps, behavioral activation, and relapse prevention) delivered by a peer interventionist plus standard of care, which is typically referral to a local outpatient substance use treatment clinic. They will also receive a Wisepill, a wireless, real-time adherence monitoring device.
- ESOC (Type: NO_INTERVENTION): Those assigned to the ESOC (enhanced standard of care) condition will receive the standard of care, which is referral to a local substance use treatment clinic. The substance use clinics in the location that this study occurs follow the Matrix, and evidence-based 16-week outpatient program to treat substance use. We will enhance patients' normal referral to Matrix for ESOC participants by promoting facilitating and following up on the referral. Additionally, those in the control group will also receive a Wisepill, a wireless adherence monitoring device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* The patient has schizophrenia, diagnosed according to DSM-IV-TR®.~* The patient has a CGI-S score from mildly ill to markedly ill at the Screening and Baseline Visit(s).~* The patient is in need of a change in the current antipsychotic treatment and in the judgement of the investigator the patient would benefit from an extended treatment with a once-monthly formulation.~* The patient agrees to protocol-defined use of effective contraception.~Main Exclusion Criteria:~* The patient has any current psychiatric disorder or Axis I disorder (DSM-IV® criteria) other than schizophrenia established as the primary diagnosis.~* The patient is experiencing acute exacerbation of psychotic symptoms at the Screening Visit or between the Screening and Baseline Visits.~* The patient in the investigator's judgment has shown significant intolerance and/or lack of efficacy to oral aripiprazole, paliperidone or risperidone.~* The patient is at significant risk of harming himself/herself or others according to the investigator's judgement or according to Columbia-Suicide Severity Rating Scale (C-SSRS).~* The patient has a history of neuroleptic malignant syndrome.~* The patient has or has had significant medical condition that would expose him or her to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the course of the study including, but not limited to neurological, hepatic, renal, metabolic, haematological, immunological, gastrointestinal, pulmonary, or cardiovascular disorders.~* The patient has a disease or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study.~* The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Aripiprazole and aripiprazole once-monthly (Type: EXPERIMENTAL): None
- Paliperidone and paliperidone palmitate (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of DHA on Periodontitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age \>40 years~* \>20 natural teeth (excluding third molars)~* no orthodontic appliances~* periodontitis defined as \>4 teeth with pocket probing depths \>5 mm~Exclusion Criteria:~* pregnancy~* diabetes~* severe chronic diseases~* gastrointestinal bleeding~* uncontrolled chronic diseases~* autoimmune disorders~* conditions requiring antibiotic prophylaxis~* warfarin~* clopidogrel~* antimicrobial therapy within 30 days~* chronic use of non-steroidal anti-inflammatory drugs (other than aspirin)~* omega-3 fatty acid use within 6 months~* loose teeth~* painful teeth~* periodontal abscess~* pocket depths \>10 mm in \>1 tooth~* periodontal therapy within the past two years~* allergy to aspirin~* allergy to fish oil~* allergy to corn oil~* allergy to soybean oil

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Aspirin & Docosahexaenoic acid (Type: EXPERIMENTAL): Aspirin 81 mg 1 tablet by mouth daily and Docosahexanoic acid (DHA) 500 mg 4 capsules by mouth daily (total daily dose of 2 grams DHA) for 3 months
- Aspirin & Placebo (Type: ACTIVE_COMPARATOR): Aspirin 81 mg by mouth daily and placebo (50% corn oil/50% soybean oil) 4 capsules by mouth daily for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Correlating Brain Tissue Oxygen and Regional Cerebral Oximetry

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are scheduled for elective removal of secondary cerebral metastases under general anesthesia.~Exclusion Criteria:~* Patients will be excluded if they refuse to give consent, have evidence of elevated intracranial pressure on preoperative CT scan, have coagulopathy, are taking therapeutic agents known to increase bleeding risk, have a history of cardiovascular disease, cerebrovascular disease, suffer from respiratory failure, or are not fluent English speakers.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Varying cerebral oxygenation with varying ventilation (Type: EXPERIMENTAL): Compare oxygenation under conditions of varying ventilation strategy. Low end tidal CO2/Low inspired oxygen vs High end tidal CO2/high inspired oxygen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Stage 1: Healthy male or female adults 50 to 64 years of age with no history of pneumococcal vaccination~* Stage 2: Healthy male or female adults 65 to 85 years of age previously vaccinated with Prevnar 13 \>= 2 months prior to investigational product administration~Exclusion Criteria:~* Stage 1: Vaccination within 12 months before investigational product administration with diphtheria-, pertussis-, or tetanus-containing vaccine~* Stage 2: Previous vaccination with any pneumococcal vaccine other than a single prior dose of Prevnar 13

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Stage 1 multivalent (ages 50-64 years) (Type: EXPERIMENTAL): multivalent
- Stage 1 Tdap (ages 50-64 years) (Type: ACTIVE_COMPARATOR): Tdap
- Stage 2 multivalent (ages 65-85 years) (Type: EXPERIMENTAL): multivalent
- Stage 2 polysaccharide (ages 65-85 years) (Type: ACTIVE_COMPARATOR): polysaccharide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or post-menopausal women between 50 and 85 years~* Clinical diagnosis of vascular dementia according to NINDS-AIREN criteria~* CT or MRI results compatible with clinical diagnosis~* MMSE score between 10 and 24, both inclusive~* Modified Hachinski Ischemic Score \>4~* Hamilton Depression Scale score of less than or equal to 15~* Adequate visual and auditory acuity to allow neuropsychological testing~* Informed consent given by the patient and/or the next-of-kin~Exclusion Criteria:~* Gastric ulcer associated with intolerance of acetylsalicylic acid treatment~* Severe psychotic features, schizophrenia, depression, agitation or behavioral problems within the last three months that could lead to difficulty complying with the protocol~* Any severe systemic illness or unstable medical condition that could lead to difficulty complying with the protocol or significantly limits life span.~* Patients who in the investigator's opinion, would not comply with study procedures~* Any significant neurological disease other than vascular dementia, such as Parkinson's disease, epilepsy, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, or multiple sclerosis~* History of alcohol or substance abuse or dependence within the past two years~* Patients with a history of systemic cancer within the past two years~* Severe congestive heart failure or malignant, uncontrollable hypertension~* Participation in a clinical trial with an investigational drug in the past four weeks

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Cerebrolysin (Type: EXPERIMENTAL): None
- 0.9% Saline Solution (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated informed consent form~* Men and women ≥ 50 years of age.~* Active predominantly classic subfoveal choroidal neovascularization (CNV) lesions secondary to wAMD (wet Age-Related Macular Degeneration)~* BCVA (best corrected visual acuity) of 20/40 to 20/320 in the study eye~Exclusion Criteria:~* Only one functional eye~* Presence of CNV with an origin other than wAMD~* Any prior ocular or systemic treatment or surgery for wAMD, except dietary supplements or vitamins

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aflibercept injection (EYLEA, VEGF Trap-Eye, BAY86-5321) (Type: EXPERIMENTAL): Participants received 2.0 mg intravitreal aflibercept injection (IAI) every 4 weeks for the first 12 weeks, followed by additional 2.0 mg IAI every 8 weeks until week 48. Additionally, sham photodynamic therapy (PDT) treatments was administered as needed.
- PDT treatments (Type: ACTIVE_COMPARATOR): Participants received PDT as needed. Additionally, sham IAI injections was administered until week 28. Thereafter, participants received active IAI treatment until week 48.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug-Drug Interaction Study Between Colchicine and Ketoconazole

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults 18-45 years of age, non-smoking and non-pregnant (post-menopausal, surgically sterile or using effective contraceptive measures) with a body mass index (BMI) greater than or equal to 18 and less than or equal to 32, inclusive~Exclusion Criteria:~* Recent participation (within 28 days) in other research studies~* Recent significant blood donation or plasma donation~* Pregnant or lactating~* Test positive at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV)~* Recent (2-year) history or evidence of alcoholism or drug abuse~* History or presence of significant cardiovascular, pulmonary, hepatic, gallbladder or biliary tract, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease~* Subjects who have used any drugs or substances known to inhibit or induce cytochrome (CYP) P450 enzymes and/or P-glycoprotein (P-gp) within 28 days prior to the first dose and throughout the study~* Drug allergies to colchicine or ketoconazole or any other anti-fungal agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Colchicine alone (Type: ACTIVE_COMPARATOR): -baseline colchicine pharmacokinetics
- Colchicine with Steady-State Ketoconazole (Type: EXPERIMENTAL): -colchicine pharmacokinetics in presence of steady-state ketoconazole

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Valganciclovir Versus Valacyclovir

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients receiving alemtuzumab~* Age \> 15~* Signed informed consent form~Exclusion Criteria:~* Active cytomegalovirus disease or infection. Asymptomatic patients with positive CMV pp65 antigenemia will not be excluded.~* Patients with a creatinine clearance of \< 10 ml/min as calculated via the Cockcroft-Gault equation.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Valacyclovir
- 2 (Type: ACTIVE_COMPARATOR): Valganciclovir

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* best corrected visual acuity of 5-65, inclusive, in study eye~* presence of choroid neovascularization secondary to AMD~* persistent edema despite at least 3 previous intravitreal anti-VEGF injections in the past 5 months~Exclusion Criteria:~* greater than 100 micron decrease in central subfield thickness on Optical Coherence Topography (OCT) since last standard of care visit~* history of major ophthalmic surgery in the study eye in the past 3 months~* history of significant ocular disease or condition other than exudative AMD that may confound results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sirolimus (Type: EXPERIMENTAL): Intravitreal Sirolimus
- Standard of Care intravitreal anti-VEGF (Type: ACTIVE_COMPARATOR): anti-VEGF intravitreal injections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete